Table 3.
Frequencies of the analyzed single-nucleotide polymorphism (SNPs), before treatment (D0) and in recurrent infections after treatment with artemether-lumefantrine (R0)
| Frequencies, (pure+mix)/total*, % (95%CI) | |||||
|---|---|---|---|---|---|
| pfmdr1 N86 | pfcrt K76 | ||||
| D0 | |||||
| All patients | (115+56)/234 | 73.1 (67.4-78.8)a | (152+41)/232 | 83.2 (78.3-88.0) | |
| Patients with recrudescence during follow-up | (5+8)/13 | 100.0 (100.0-100.0) | (7+5)/13 | 92.3 (75.6-100.0) | |
| Patients with reinfection during follow-up | (53+33)/115 | 74.8 (66.7-82.8)b | (71+23)/113 | 83.2 (76.2-90.2) | |
| R0 | |||||
| All patients | (99+30)/138 | 93.5 (89.3-97.7)a | (92+15)/126 | 84.9 (78.6-91.3) | |
| Patients with recrudescence | (12+2)/14 | 100.0 (100.0-100.0) | (9+2)/13 | 84.6 (61.9-100.0) | |
| Patients with new infection | (79+25)/112 | 92.9 (88.0-97.7)b | (74+13)/104 | 83.7 (76.4-90.9) | |
* denotes the total no of successful analyses; CI, confidence interval
* denotes the total no of successful analyses; CI, confidence interval
aStatistically significant increase between baseline and all recurrent infections, P < 0.0001
bStatistically significant increase between baseline and only reinfections, P = 0002